Chromosomes are the structures within cells that carry genetic information, and abnormalities in their number or structure are associated with a wide range of developmental, intellectual, and medical conditions. Cytogenetic testing is the category of laboratory investigation designed to detect these chromosomal abnormalities, and the methods available within this category have expanded significantly over the past two decades, moving from techniques that could identify large chromosomal changes to approaches that can detect alterations too small to be seen by conventional methods.
Understanding what different cytogenetic approaches can and cannot detect helps clinicians order the right test for the clinical question being asked, and helps patients and families understand why one type of testing was recommended over another.
Conventional Chromosome Analysis and Its Limitations
The most established form of cytogenetic testing is conventional karyotyping, which creates a visual map of the complete chromosome set from cultured cells. This approach successfully identifies large-scale structural and numerical anomalies, such as:
- Numerical Abnormalities: Aneuploidies including trisomies (e.g., Trisomy 21 / Down syndrome), where a third copy of a chromosome is present.
- Macro-Structural Rearrangements: Large-scale deletions, duplications, inversions, and balanced or unbalanced translocations affecting significant chromosomal regions.
Limitation: Conventional karyotyping is limited by microscopic resolution (typically ~5–10 Mb). Deletions or duplications below this size threshold, known as microdeletions and microduplications, cannot be visualized via standard karyotyping and require higher-resolution molecular techniques.
What Chromosomal Microarray Analysis Detects
Chromosomal microarray analysis, also called cytogenetic microarray testing, addresses the resolution limitation of conventional karyotyping by scanning the entire genome at much higher resolution. The technique can identify small deletions and duplications, collectively called copy number variants, across the full genome simultaneously. Many of the genetic conditions associated with intellectual disability, autism spectrum disorder, developmental delay, and congenital anomalies are caused by copy number variants that fall below the detection threshold of conventional karyotyping and would be missed without microarray analysis.
The cytogenetic microarray testing available through MedGenome provides genome-wide copy number variant detection at a resolution that conventional karyotyping cannot achieve, covering the range of chromosomal changes that are clinically relevant in both prenatal and postnatal diagnostic contexts.
Clinical Contexts Where Cytogenetic Testing Is Used
In prenatal diagnosis, cytogenetic testing is used to follow up on abnormal screening results, to investigate structural abnormalities identified on ultrasound, and in some cases as a first-line investigation when the clinical indication warrants it. Chromosomal microarray is now recommended in many clinical guidelines as the first-line cytogenetic test for fetuses with structural abnormalities, because it detects a higher proportion of clinically relevant findings than conventional karyotyping in this context.
In postnatal diagnosis, cytogenetic testing is used in children with unexplained intellectual disability, developmental delay, autism spectrum disorder, congenital anomalies, or growth abnormalities where a chromosomal cause is suspected. The diagnostic yield of microarray in these populations is substantially higher than that of conventional karyotyping for the same reason: the conditions that cause these presentations are more commonly caused by small copy number variants than by the large chromosomal changes that karyotyping detects.
In oncology, cytogenetic testing serves a different purpose, identifying the chromosomal changes that characterize specific cancer types and that have diagnostic, prognostic, and treatment selection implications. Cytogenetic testing cancer applications cover a range of hematological malignancies and solid tumors where chromosomal analysis contributes to diagnosis and management decisions.
What a Result Means
A cytogenetic microarray result reports any copy number variants detected in the sample, classified according to their likely clinical significance. Pathogenic variants are those with established associations with clinical conditions. Variants of uncertain significance are those where the available evidence does not yet allow a definitive classification as either causing or not causing a condition. Benign variants are common in the population and not associated with clinical problems.
The variant of uncertain significance category is one that families often find difficult to navigate, because it does not provide the definitive answer that the testing was intended to deliver. The classification of these variants changes over time as more data accumulates, and some variants that are uncertain today will be reclassified as more evidence becomes available.
